摘要:
The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.
摘要翻译:本发明涉及由式[I]表示的化合物或其药学上可接受的盐或酯,其中R 1和R 2可以相同或不同,分别为氢原子,低级烷基,环烷基 ,等等; R 3和R 4可以相同或不同,分别为氢原子,低级烷基,NR a R b,苯基,被苯基取代的低级烷基,4-至7-元脂族杂环基, 被4-至7-元脂族杂环基取代的低级烷基,5或6元芳族杂环基,被5或6元芳族杂环基取代的低级烷基等; R5为氢原子,氰基,卤素原子或低级烷基。
摘要:
The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1′, R2, R2′, R3, R3′, R4, and R4′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.
摘要翻译:本发明涉及由式[I]表示的化合物或其药学上可接受的盐或酯:其中:X 1,X 2,X 3, / SUB>和X 4可以相同或不同,各自为C或N,条件是X 1,X 2, / SUB>,X 3和X 4是N; Y是CH或N; R 1,R 1,R 2,R 2,R 3,N 3, R 3,R 4,R 4,R 4和R 4可以相同或不同,分别为氢原子,低级 烷基等; R 5是氢原子或甲基; R 6和R 7可以相同或不同,分别为氢原子,低级烷基等; R 8和R 8可以相同或不同,分别为氢原子,低级烷基等; R 9是可以被取代的芳基或杂芳基; n为1〜3的整数,PLK1抑制剂或含有该PLK1抑制剂的抗癌剂。
摘要:
The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1′, R2, R2′, R3, R3′, R4, and R4′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.
摘要翻译:本发明涉及由式[I]表示的化合物或其药学上可接受的盐或酯:其中:X 1,X 2,X 3和X 4可以相同或不同,各自为C或N,条件是 X1,X2,X3和X4中的两个为N; Y是CH或N; R1,R1',R2,R2',R3,R3',R4和R4'可以相同或不同,分别为氢原子,低级烷基等; R5是氢原子或甲基; R 6和R 7可以相同或不同,分别为氢原子,低级烷基等; R 8和R 8'可以相同或不同,分别为氢原子,低级烷基等; R9是可以被取代的芳基或杂芳基; n为1〜3的整数,PLK1抑制剂或含有该PLK1抑制剂的抗癌剂。
摘要:
The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4-to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5-or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5-or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.
摘要翻译:本发明涉及由式[I]表示的化合物或其药学上可接受的盐或酯,其中R 1和R 2可以相同或不同,分别为氢原子,低级烷基,环烷基 ,等等; R 3和R 4可以相同或不同,分别为氢原子,低级烷基,NR a R b,苯基,被苯基取代的低级烷基,4-至7-元脂族杂环基, 被4〜7元脂肪族杂环基取代的低级烷基,5元或6元芳族杂环基,被5元或6元芳族杂环基取代的低级烷基等。 R5为氢原子,氰基,卤素原子或低级烷基。
摘要:
The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6′, are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.
摘要翻译:本发明涉及由式[I]表示的化合物:其中:A环是含有至少一个选自氮原子的杂原子的5元芳族杂环基等; A 1和A 2分别是氮原子等; X 2,X 3,X 4和X 5都是碳原子,或者任意一个 X 2,X 3,X 4和X 5是氮原子,其余全部是碳 原子 R 1是氢原子等; R 2,R 3,R 4和R 5各自为氢原子等 ; R 6和R 6'各自为氢原子等; R 7是芳基等; 并且R 8是氨基或羟基,或其药学上可接受的盐或酯。
摘要:
The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6′, are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.
摘要:
The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
摘要翻译:本发明涉及具有葡糖激酶活化作用并可用作糖尿病治疗剂的化合物,其由式(I)表示:其中X 1表示氮原子, 硫原子,氧原子等; R 1表示6至10元芳基,5至7元杂芳基等; D表示氧原子或硫原子; R和R 3相同或不同,各自表示氢原子,低级烷基等; 式(II)表示任选取代的5〜7元杂芳基等; 式(III)表示单环或双环杂芳基]或其药学上可接受的盐。
摘要:
This invention provides substituted heteroaromatic ring derivatives which are represented by a general formula [I] below: ##STR1## [in the formula, R.sup.1 and R.sup.2 may be same or different and each signifies hydrogen, halogen or lower alkyl; R.sup.3 signifies C.sub.3 -C.sub.6 cycloalkyl or cycloalkenyl; R.sup.4 signifies a heteroaromatic ring group which may be condensed with a benzene ring and which has 1 or 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulfur atoms (said heteroaromatic ring group being optionally substituted with lower alkyl, halogen, lower alkoxy, amino or hydroxymethyl); and X stands for O or NH]or their pharmaceutically acceptable salts.The substituted heteroaromatic ring derivatives of the present invention have selective M.sub.3 muscarinic receptor antagonist activity, and hence they are useful as therapeutic or prophylactic agents which are safe and efficacious with little side effects, of respiratory diseases such as asthma, chronic airway obstruction and pulmonary fibrosis, etc.; urinary diseases which induce such urination disorders as pollakiurea, urgency and urinary incontinence, etc.; and gastrointestinal diseases such as irritable bowel syndrome, spasm of gastrointestinal tract and gastrointestinal hyperkinesis.